Satoreotide trizoxetan clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses satoreotide trizoxetan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Satoreotide tetraxetan (1)
Studies
Open first, then newest update. How each study uses satoreotide trizoxetan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)TerminatedPhase 1/2IpsenNCT03773133Written as Satoreotide trizoxetanHow we know
- Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast CancerTerminatedPhase 2IpsenNCT03697551Written as Satoreotide trizoxetanHow we know
- 68Ga-OPS202 Study for Diagnostic Imaging of GEP NETCompletedPhase 1/2IpsenNCT02162446Written as satoreotide trizoxetanHow we know
Codes
What other systems call satoreotide trizoxetan · ClinicalTrials.gg INT014695
- UNII (FDA) 3M7TX701A4SATOREOTIDE TRIZOXETANOne source FDA
- NCI Thesaurus C166683Satoreotide TrizoxetanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3M7TX701A4 | SATOREOTIDE TRIZOXETAN | One source FDA |
| NCI Thesaurus | C166683 | Satoreotide Trizoxetan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.